Savient Pharmaceuticals (SVNTQ) Stock Price, News & Analysis

Company Overview

Savient Pharmaceuticals, formerly known as Bio-Technology General Corp., was a specialty biopharmaceutical company focused on developing and commercializing therapies for serious and often underserved medical conditions. The company was headquartered in East Brunswick, New Jersey, and served primarily the U.S. market while also pursuing international opportunities for selected products.

Savient’s principal product was KRYSTEXXA (pegloticase), an enzyme replacement therapy approved in the United States for adults with chronic gout that is refractory to conventional treatment. The company also marketed Oxandrin (oxandrolone), an anabolic steroid used for certain weight-gain and recovery indications, although the product was later divested.

After experiencing commercial and financial difficulties, Savient filed for Chapter 11 bankruptcy protection in 2013. Its KRYSTEXXA business was acquired by Crealta Pharmaceuticals, which was subsequently acquired by Horizon Pharma. Savient Pharmaceuticals is no longer an operating public company, and its former OTC quotation, SVNTQ, reflects its post-bankruptcy status.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 340,036 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Industrials
• Industry: Medicinal Chemicals
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:SVNTQ
• Previous Symbol: NASDAQ:SVNT
• CIK: 722104
• Web: www.savientpharma.com
• Phone: +1-732-4189300
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A